{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:29:16Z","timestamp":1789504156052,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI161943"],"award-info":[{"award-number":["P30AI161943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI168439"],"award-info":[{"award-number":["P30AI168439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025931","name":"Toe River Arts Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["1R56AI184089-01A1"],"award-info":[{"award-number":["1R56AI184089-01A1"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["1K01OD031898-01"],"award-info":[{"award-number":["1K01OD031898-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["1R21AI170148-01"],"award-info":[{"award-number":["1R21AI170148-01"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tim.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:37:42Z","timestamp":1746751062000},"page":"961-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in host-directed therapy for tuberculosis and HIV coinfection: enhancing immune responses"],"prefix":"10.1016","volume":"33","author":[{"given":"Preena","family":"Prasanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry S.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Paiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riti","family":"Sharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2025.04.006_bb0005","series-title":"Tuberculosis","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.tim.2025.04.006_bb0010","series-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.tim.2025.04.006_bb0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017871","article-title":"Tuberculosis and HIV coinfection","volume":"5","author":"Bruchfeld","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107706","article-title":"Mycobacterium tuberculosis impairs human memory CD4(+) T cell recognition of M2 but not M1-like macrophages","volume":"26","author":"Gail","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.tim.2025.04.006_bb0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2249.2001.01401.x","article-title":"Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients","volume":"123","author":"Toossi","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0030","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.1000135","article-title":"Sub-optimal CD4 T-lymphocyte responses among HIV infected patients who develop TB during the first year of ART","volume":"3","author":"Eshun-Wilson","year":"2012","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.tim.2025.04.006_bb0035","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2334-14-468","article-title":"The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study","volume":"14","author":"Assefa","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0040","article-title":"Host-directed therapy as a novel treatment strategy to overcome tuberculosis: targeting immune modulation","volume":"9","author":"Ahmed","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.tim.2025.04.006_bb0045","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1172\/JCI136502","article-title":"Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model","volume":"130","author":"Ganatra","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.04.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153090","article-title":"Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis\/SIV coinfection model","volume":"132","author":"Sharan","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.04.006_bb0055","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.aids.0000238406.93249.cd","article-title":"Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control","volume":"20","author":"Lawn","year":"2006","journal-title":"Aids"},{"key":"10.1016\/j.tim.2025.04.006_bb0060","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1172\/JCI125810","article-title":"Mechanisms of reactivation of latent tuberculosis infection due to SIV coinfection","volume":"129","author":"Buc\u015fan","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.04.006_bb0065","doi-asserted-by":"crossref","first-page":"E5636","DOI":"10.1073\/pnas.1611987113","article-title":"CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection","volume":"113","author":"Foreman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2025.04.006_bb0070","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tim.2020.03.015","article-title":"Chronic immune activation in TB\/HIV co-infection","volume":"28","author":"Sharan","year":"2020","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tim.2025.04.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003875","article-title":"Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: interim analysis of a hybrid type 3 effectiveness-implementation randomized trial","volume":"18","author":"Semitala","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0080","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/QAD.0000000000003508","article-title":"Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3months weekly isoniazid-rifapentine","volume":"37","author":"Chaisson","year":"2023","journal-title":"Aids"},{"key":"10.1016\/j.tim.2025.04.006_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706723","article-title":"Characterizing early T cell responses in nonhuman primate model of tuberculosis","volume":"12","author":"Sharan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0090","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/infdis\/jiy052","article-title":"Human immunodeficiency virus infection impairs Th1 and Th17 Mycobacterium tuberculosis-specific T-cell responses","volume":"217","author":"Murray","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0095","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4049\/jimmunol.1003009","article-title":"Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection","volume":"186","author":"Novy","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0100","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1038\/s41467-021-23189-7","article-title":"IL-21 and IFN\u03b1 therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques","volume":"12","author":"Harper","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.04.006_bb0105","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1128\/JVI.01476-10","article-title":"Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers","volume":"85","author":"Williams","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2025.04.006_bb0110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/srep36720","article-title":"IL-21 signaling is essential for optimal host resistance against Mycobacterium tuberculosis infection","volume":"6","author":"Booty","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2025.04.006_bb0120","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.4049\/jimmunol.1601231","article-title":"IL-21 Receptor signaling is essential for optimal CD4(+) T cell function and control of Mycobacterium tuberculosis infection in mice","volume":"199","author":"Cheekatla","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0125","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1089\/aid.2017.0160","article-title":"IL-21 Therapy controls immune activation and maintains antiviral CD8(+) T cell responses in acute simian immunodeficiency virus infection","volume":"33","author":"M\u00e9ndez-Lagares","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.tim.2025.04.006_bb0130","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1172\/JCI81400","article-title":"Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques","volume":"125","author":"Micci","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2025.04.006_bb0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2011.599","article-title":"A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer","volume":"106","author":"Steele","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tim.2025.04.006_bb0140","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1158\/1078-0432.CCR-10-1809","article-title":"Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial","volume":"16","author":"Schmidt","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tim.2025.04.006_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1369743","article-title":"Therapeutic potential of interleukin-21 in cancer","volume":"15","author":"Isvoranu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0150","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tim.2025.04.006_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10020-021-00320-4","article-title":"Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time","volume":"27","author":"T\u00e9llez-Navarrete","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0160","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/jiu206","article-title":"Tumor necrosis factor alpha is associated with viral control and early disease progression in patients with HIV type 1 infection","volume":"210","author":"Vaidya","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/rmv.369","article-title":"The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages","volume":"13","author":"Kedzierska","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.tim.2025.04.006_bb0170","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.tim.2025.04.006_bb0175","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(24)00512-7","article-title":"Advancing the chemotherapy of tuberculous meningitis: a consensus view","volume":"25","author":"Wasserman","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10096-023-04564-2","article-title":"The use of TNF-\u03b1 antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature review","volume":"42","author":"Armange","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-3-8","article-title":"LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells","volume":"3","author":"Haraguchi","year":"2006","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.tim.2025.04.006_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12879-016-2097-7","article-title":"Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report","volume":"17","author":"Mu\u00f1oz-Oca","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.tim.2025.04.006_bb0200","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/biom14070848","article-title":"Role of type I interferons during Mycobacterium tuberculosis and HIV infections","volume":"14","author":"Anes","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.tim.2025.04.006_bb0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jis663","article-title":"Pegylated interferon Alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration","volume":"207","author":"Azzoni","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0210","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.4049\/jimmunol.1401088","article-title":"Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-\u03b3 for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages","volume":"193","author":"McNab","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0215","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1038\/s41467-022-30914-3","article-title":"Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx","volume":"13","author":"Kang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2025.04.006_bb0220","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0225","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20180325","article-title":"Type I interferons in tuberculosis: foe and occasionally friend","volume":"215","author":"Moreira-Teixeira","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660916","article-title":"Host-directed therapies: modulating inflammation to treat tuberculosis","volume":"12","author":"Krug","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0235","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa2216218","article-title":"Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults","volume":"389","author":"Donovan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0240","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.4049\/jimmunol.0902626","article-title":"Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses","volume":"185","author":"Leone","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1086\/653827","article-title":"Coadministration of interleukins 7 and 15 with bacille Calmette-Gu\u00e9rin mounts enduring T cell memory response against Mycobacterium tuberculosis","volume":"202","author":"Singh","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0250","article-title":"Immunomodulation with IL-7 and IL-15 in HIV-1 infection","volume":"9","author":"Gunst","year":"2023","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.tim.2025.04.006_bb0255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12916-016-0635-1","article-title":"Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis","volume":"14","author":"Zumla","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0260","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","article-title":"Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial","volume":"28","author":"Miller","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00372-22","article-title":"The HIV latency reversal agent HODHBt enhances NK cell effector and memory-like functions by increasing interleukin-15-mediated STAT activation","volume":"96","author":"Macedo","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2025.04.006_bb0270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1164\/rccm.200211-1359OC","article-title":"Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis","volume":"168","author":"Johnson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0275","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1183\/09031936.01.17510490","article-title":"Interleukin-12 as successful adjuvant in tuberculosis treatment","volume":"17","author":"Greinert","year":"2001","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.tim.2025.04.006_bb0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1084\/jem.186.1.39","article-title":"Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis","volume":"186","author":"Cooper","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00263-17","article-title":"DNA priming increases frequency of T-cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8(+) T-cell responses by interleukin-12 plasmid DNA","volume":"24","author":"Li","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0290","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1189\/jlb.0708438","article-title":"Immune activation and IL-12 production during acute\/early HIV infection in the absence and presence of highly active, antiretroviral therapy","volume":"84","author":"Byrnes","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.tim.2025.04.006_bb0295","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1093\/cid\/civ615","article-title":"T-cell therapy: options for infectious diseases","volume":"61Suppl 3","author":"Parida","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0300","article-title":"Case report: active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.tim.2025.04.006_bb0305","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/COH.0000000000000485","article-title":"Chimeric antigen receptor T-cell approaches to HIV cure","volume":"13","author":"Kuhlmann","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tim.2025.04.006_bb0310","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2025.04.006_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.655363","article-title":"Editorial: immunotherapies towards HIV cure","volume":"11","author":"Salgado","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.tim.2025.04.006_bb0320","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/cco-23-153","article-title":"A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment","volume":"13","author":"Hirano","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.tim.2025.04.006_bb0330","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tim.2025.04.006_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115738","article-title":"Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis","volume":"168","author":"Arnett","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tim.2025.04.006_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1033609","article-title":"Prime, shock and kill: BCL-2 inhibition for HIV cure","volume":"13","author":"Chandrasekar","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0345","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1021\/acsinfecdis.4c00639","article-title":"Efficacy and possible mechanism(s) of action of gallium tetraphenylporphyrin nanoparticles against HIV-TB coinfection in an in vitro granuloma structure model","volume":"10","author":"Choi","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.tim.2025.04.006_bb0350","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179317","article-title":"Indoleamine-2,3-dioxygenase inhibition improves immunity and is safe for concurrent use with cART during Mtb\/SIV coinfection","volume":"9","author":"Singh","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.tim.2025.04.006_bb0355","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/ph17101355","article-title":"Pharmaceutical agents for targeting autophagy and their applications in clinics","volume":"17","author":"Kench","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tim.2025.04.006_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.848373","article-title":"Editorial: repurposed drugs as immune-modulators to combat infectious diseases","volume":"13","author":"Mishra","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2025.04.006_bb0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/fvl-2019-0069","article-title":"The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication","volume":"15","author":"Waters","year":"2020","journal-title":"Future Virol."},{"key":"10.1016\/j.tim.2025.04.006_bb0370","article-title":"Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis","volume":"11","author":"Vega","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.tim.2025.04.006_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002714","article-title":"Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes","volume":"4","author":"Geiger","year":"2024","journal-title":"PLOS Glob. Public Health"},{"key":"10.1016\/j.tim.2025.04.006_bb0380","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tube.2016.02.010","article-title":"HIV-1 and the Mycobacterium tuberculosis granuloma: a systematic review and meta-analysis","volume":"98","author":"Diedrich","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tim.2025.04.006_bb0385","article-title":"Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation","author":"Sharan","year":"2024","journal-title":"Res. Sq."},{"key":"10.1016\/j.tim.2025.04.006_bb0390","first-page":"123","article-title":"Next-generation cytokines for cancer immunotherapy","volume":"4","author":"Xue","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.tim.2025.04.006_bb0395","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2012.11.005","article-title":"Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection","volume":"66","author":"Mihret","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2025.04.006_bb0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X25001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X25001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:00:25Z","timestamp":1757070025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X25001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0966842X25001179"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2025.04.006","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in host-directed therapy for tuberculosis and HIV coinfection: enhancing immune responses","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}